Kiadis Pharma expands presence in the United States
04 Janvier 2019 - 07:00AM
Kiadis Pharma
expands presence in the United States
Scott Holmes
commences position as chief financial officer
Amy Sullivan appointed senior vice president,
corporate affairs
Both are based in Boston, Massachusetts
Amsterdam, The
Netherlands, and Boston, Massachusetts, USA - January 4, 2019 -
Kiadis Pharma N.V. ("Kiadis" or the "Company") (Euronext Amsterdam
and Brussels: KDS), a clinical-stage biopharmaceutical company,
today announces that it has expanded its presence in the United
States. Two of Kiadis' key interfaces for the financial markets are
now based in Boston, with the previously announced appointment of
Scott Holmes as chief financial officer and today's announcement of
Amy Sullivan as senior vice president of corporate affairs, both
effective January 1, 2019. Ms. Sullivan will replace Karl Hård, who
resigned effective December 31st to pursue
other interests.
Arthur Lahr, CEO
of Kiadis Pharma, commented: "I would like start by thanking
Karl for his service to Kiadis and wishing him well in all his
future endeavors. I am excited to officially welcome both
Scott and Amy to our company. They are a strong team and together
bring a wealth of capital markets experience and strong
relationships with the financial community to our company. I
look forward to working with them as we continue to raise awareness
of Kiadis within the financial markets, as well as the medical
community, in both the US and Europe."
Ms. Sullivan is a seasoned
corporate affairs professional with more than 25 years of
experience raising capital and building and managing corporate
biotechnology and life sciences brands. Ms. Sullivan joins
Kiadis from Keryx Biopharmaceuticals where she was senior vice
president of corporate affairs, responsible for all aspects of
investor relations, corporate communication, and public affairs,
during a period of high growth, commercialization of the company's
first FDA-approved medicine and, ultimately, a merger. Prior to
Keryx, Ms. Sullivan served as head of corporate communications and
investor relations at AMAG Pharmaceuticals, Idenix
Biopharmacueticals and Genencor International. Earlier in her
career, Ms. Sullivan served in roles of increasing responsibility
in both agencies and Fortune 500 companies. Ms. Sullivan has her
bachelor of science degree in business from Salem State University
and her masters of business administration from Bentley
University.
Along with Mr. Holmes, Ms.
Sullivan will be based in Boston. She will be responsible for
investor relations, corporate communications and public affairs for
Kiadis.
For more
information, please contact:
Kiadis Pharma:
Amy Sullivan, SVP, Corporate Affairs
Tel. +1 508 479 3480
a.sullivan@kiadis.com |
Optimum Strategic Communications:
Mary Clark, Supriya Mathur, Hollie Vile
Tel: +44 203 714 1787
David Brilleslijper (Amsterdam)
Tel: +31 610 942 514
kiadis@optimumcomms.com
|
About Kiadis
Pharma
Kiadis Pharma is developing its lead product candidate, ATIR101,
for use in conjunction with haploidentical HSCT for adult blood
cancers to address key limitations of haploidentical HSCT, without
prophylactic immunosuppression and its associated morbidity and
mortality. Based on the positive results from the single dose Phase
II CR-AIR-007 study, the Company submitted a marketing
authorization application to the European Medicines Agency in April
2017 for approval of ATIR101 as an adjunctive treatment in
haploidentical HSCT for high risk adult hematological malignancies.
If the product is conditionally approved, Kiadis Pharma intends to
launch ATIR101 in selected countries in Europe through its own
commercial organization starting in the second half of 2019.
In December 2017, Kiadis Pharma
commenced an international, multicenter, randomized and controlled
Phase III clinical trial of ATIR101 against the Post-Transplant
Cyclophosphamide, or PTCy protocol, the main protocol used to
perform a haploidentical HSCT. The trial will be performed in 250
patients with acute leukemia and myelodysplastic syndrome at
approximately 50 sites in the United States, Canada, Europe and
certain additional countries. ATIR101 received regenerative
medicine advanced therapy designation from the FDA in September
2017, which provides benefits that are materially equivalent to a
breakthrough designation from the FDA. In addition, ATIR101 has
been granted multiple orphan drug designations both in the European
Union and the United States.
The Company's shares are listed on
Euronext Amsterdam and Brussels under the ticker KDS.
Forward Looking
Statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect Kiadis Pharma's
or, as appropriate, Kiadis Pharma's directors' current expectations
and projections about future events. By their nature,
forward-looking statements involve a number of risks, uncertainties
and assumptions that could cause actual results or events to differ
materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. A multitude of factors including, but not
limited to, changes in demand, competition and technology, can
cause actual events, performance or results to differ significantly
from any anticipated development. Forward looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis Pharma
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or any change in
events, conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis Pharma nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person's officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Kiadis Pharma N. V. via Globenewswire